LEIDEN, Netherlands, April 26,
2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming")
(Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that
Pharming's Chief Executive Officer, Sijmen de Vries will attend the
H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New
York and will take part in a fireside chat at 11:00 ET/17:00
CEST.
Pharming's CEO will be available for one-to-one investor
meetings during the conference.
For more information about the conference, or to schedule a
one-to-one with Pharming's management team, please contact your
H.C. Wainwright representative, or send an email to Pharming's
Investor Relations team to investor@pharming.com.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is
a global biopharmaceutical company dedicated to transforming the
lives of patients with rare, debilitating, and life-threatening
diseases. Pharming is commercializing and developing an innovative
portfolio of protein replacement therapies and precision medicines,
including small molecules, biologics, and gene therapies that are
in early to late-stage development. Pharming is headquartered in
Leiden, Netherlands, and has
employees around the globe who serve patients in over 30 markets in
North America, Europe, the Middle
East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and find us on
LinkedIn.
For further public information, contact:
Pharming Group, Leiden, The
Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
Heather Robertson, Investor
Relations & Corporate Communications Manager
E: investor@pharming.com
FTI Consulting, London,
UK Victoria Foster Mitchell/Alex Shaw/Amy Byrne T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands Leon
Melens T: +31 6 53 81 64 27 E: pharming@lifespring.nl
Logo:
https://mma.prnewswire.com/media/2003587/4004079/Pharming_Group_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/pharming-to-attend-the-hc-wainwright-bioconnect-investor-conference-2023-301807076.html